查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1951281

臨床試驗用品市場－全球產業規模、佔有率、趨勢、機會及預測（依臨床階段、產品/服務、治療用途、最終用戶、地區及競爭格局分類，2021-2031年）

Clinical Trial Supplies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Clinical Phase, By Product & Services, By Therapeutic Use, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球臨床試驗用品市場預計將從 2025 年的 31.8 億美元成長到 2031 年的 49.8 億美元，複合年成長率為 7.76%。

此業務板塊涵蓋範圍廣泛，包括臨床實驗藥物、醫療設備以及檢測套組、包裝材料等輔助用品，這些都是合規研究不可或缺的環節。成長的主要驅動力來自全球臨床試驗數量的增加以及生物製藥行業研發投入的不斷成長。此外，對生物製藥和孤兒藥日益成長的關注也需要專業的處理和物流，從而推動了對安全可靠的供應鏈解決方案的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 31.8億美元
市場規模：2031年 49.8億美元
複合年成長率：2026-2031年 7.76%
成長最快的細分市場 製藥
最大的市場 北美洲

然而，市場面臨著與複雜低溫運輸管理相關的重大障礙，尤其是對溫度敏感的生物製藥，這些製品在運輸過程中需要嚴格的環境控制。不同地區的法規差異也帶來了合規的挑戰，可能導致供應延遲和營運成本增加。歐洲製藥工業協會聯合會（EFPIA）的報告顯示，到2024年，“歐洲以研發為基礎的製藥行業預計將在研發方面投入550億歐元”，這表明構建這一基礎設施所需的投資規模巨大，也凸顯了建立高效供應鏈以維持如此巨額投資的必要性。

市場促進因素

不斷上漲的醫藥和生物製藥研發成本是推動全球臨床試驗供應市場發展的主要因素。隨著企業尋求治療慢性病和罕見疾病的新治療方法，財務支出必然需要增加臨床實驗藥物及相關耗材的購買。這種投資的增加推動了對精準供應鏈物流的需求，以管理全球各地設施的物資配送。例如，羅氏公司於2025年1月發布的《2024年財務報告》預測，該公司研發成本將達到130億瑞士法郎，顯示在治療方法開發上投入龐大。這需要大量的臨床供應支援。

同時，全球註冊的臨床試驗數量不斷增加，顯著擴大了供應商的業務範圍，也推動了市場成長。這種成長，尤其是對於複雜的生物製藥而言，需要強大的基礎設施來確保產品品質和在不同地區的及時企業發展。根據美國國立衛生研究院 (NIH) 於 2025 年 4 月發表的題為《ClinicalTrials.gov：25 年註冊 50 萬項研究的征程》的報導，該註冊系統將於 2024 年註冊其第 50 萬項臨床研究，凸顯了需要供應鏈管理的龐大研究規模。為了因應這一日益成長的需求，Cencora 在 2025 年 11 月發布的新聞稿《Cencora 宣布投資 10 億美元》中宣布，計劃在 2030 年投資 10 億美元，以加強其藥品分銷網路。

市場挑戰

低溫運輸管理的複雜性對全球臨床試驗供應市場的發展構成重大障礙。隨著產業向生物製藥和孤兒藥領域轉型，嚴格的環境控制要求使得物流結構變得特別複雜。這些對溫度敏感的產品從生產到給藥都需要持續冷藏或冷凍。運輸過程中的溫度波動會導致臨床實驗藥物失效，造成重大經濟損失並延誤試驗。這種脆弱性迫使企業投入高昂成本用於專用包裝和監控系統，從而加劇預算壓力，並限制了基礎設施低度開發地區市場的有效擴張。

目前正在研發的敏感治療藥物數量龐大，進一步加劇了物流壓力。根據美國藥品研究與製造商協會（PhRMA）預測，到2024年，全球將有超過8,000種藥物處於臨床研發階段，其中大部分是需要嚴格溫度控制的生物製藥。如此龐大數量的溫控產品運輸管理難度增加，導致廢棄物風險上升。在複雜的環境下，供應鏈中斷的可能性增加，限制了臨床試驗向新地區的拓展，並抑制了整個供應市場的成長潛力。

市場趨勢

臨床試驗（DCT）供應物流向分散式模式的轉變正在重塑市場格局，將治療點從標準研究機構轉移到患者家中。這種模式需要靈活的供應鏈，以便在嚴格控制溫度和監管鏈的前提下，將藥品直接送達患者手中。為了支援這種分散式模式，物流供應商正在建造超區域配銷中心，以確保即使在傳統臨床環境之外也能遵守通訊協定。 2025年4月發布的新聞稿「DHL集團計畫在2030年向DHL健康物流投資20億歐元」便是這項轉變的有力佐證。 DHL集團在新聞稿中宣布，將投資20億歐元以加強其生命科學物流業務，尤其旨在滿足複雜試驗設計中對專業服務的需求。

同時，人工智慧 (AI) 與需求預測的整合正在推動預測性庫存管理的發展。透過分析患者入組率和使用模式等數據，AI 演算法能夠準確預測供應需求，從而最大限度地減少藥物浪費並防止短缺。這項功能使申辦方能夠即時調整其交付策略，確保在需要時獲得充足的供應。例如，賽默飛世爾科技在 2025 年 10 月的新聞稿《賽默飛世爾科技攜手 OpenAI 加速生命科學領域的突破》中指出，該公司正在其 PPD 臨床研究部門部署人工智慧，以「縮短」臨床試驗週期並加快藥物研發。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球臨床試驗用品市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依臨床階段（I期、II期、III期、其他）
    • 依產品/服務（製造、倉儲/配送、供應鏈管理）分類
    • 依治療用途（腫瘤、中樞神經系統疾病、心血管疾病、感染疾病、代謝性疾病、其他）
    • 按最終使用者（藥品、生物藥品、醫療設備、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美臨床試驗用品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲臨床試驗用品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太臨床試驗用品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲臨床試驗用品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲臨床試驗用品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球臨床試驗用品市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific Inc.
  • Almac Group
  • Novo Holdings A/S
  • Marken LLP
  • PCI Pharma Services
  • Sharp Services LLC
  • Cencora, Inc.
  • Myonex LLC
  • Parexel International Corporation
  • ICON Plc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 15860

The Global Clinical Trial Supplies Market is projected to expand from USD 3.18 Billion in 2025 to USD 4.98 Billion by 2031, registering a CAGR of 7.76%. This sector encompasses a wide array of necessities, including investigational medicinal products, medical devices, and ancillary items like testing kits and packaging essential for compliant studies. Growth is largely fueled by the escalating number of clinical trials globally and rising research and development investments within the biopharmaceutical industry. Furthermore, the increasing emphasis on biologics and orphan drugs requires specialized handling and logistics, thereby boosting the demand for secure and resilient supply chain solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.18 Billion
Market Size 2031USD 4.98 Billion
CAGR 2026-20317.76%
Fastest Growing SegmentPharmaceutical
Largest MarketNorth America

However, the market encounters substantial obstacles related to complex cold chain management, especially for temperature-sensitive biologics that require rigorous environmental controls during transit. Varying regulations across different regions also introduce compliance difficulties that can delay supply schedules and raise operational expenses. Highlighting the scale of investment requiring this infrastructure, the 'European Federation of Pharmaceutical Industries and Associations' reported in '2024' that 'the research-based pharmaceutical industry invested an estimated 55,000 million euros in research and development in Europe', confirming the vital need for efficient supply chain mechanisms to sustain such significant financial commitments.

Market Driver

Rising pharmaceutical and biopharmaceutical R&D spending acts as a major engine for the Global Clinical Trial Supplies Market. As companies strive to discover new treatments for chronic and rare conditions, their financial outlays necessitate a corresponding increase in acquiring investigational products and ancillary supplies. This heightened investment drives the demand for precise supply chain logistics to handle material distribution across global sites. For instance, according to Roche, January 2025, in the 'Finance Report 2024', the company's research and development expenditure hit 'CHF 13.0 billion', illustrating the massive capital directed toward therapeutic advancement that requires extensive clinical supply backing.

Concurrently, the market is propelled by the growing volume of registered clinical trials worldwide, which significantly broadens the operational landscape for vendors. This increase, especially with complex biologics, calls for strong infrastructure to guarantee product quality and timely delivery across varied locations. According to the National Institutes of Health, April 2025, in the article 'ClinicalTrials.gov: A 25-Year Journey to a Half-Million Registered Studies', the registry recorded its '500,000th' clinical study in 2024, emphasizing the vast scale of research needing supply management. To meet these rising needs, according to Cencora, November 2025, in the 'Cencora Announces $1 Billion Investment' press release, the firm intends to invest '$1 billion' through 2030 to strengthen its pharmaceutical distribution network.

Market Challenge

The intricacies of cold chain management present a significant hurdle to the advancement of the global clinical trial supplies market. With the industry pivoting toward biologics and orphan drugs, the necessity for stringent environmental controls results in a delicate logistical framework. These temperature-sensitive items require continuous refrigeration or freezing from production through to administration; any temperature deviation during transport can spoil investigational products, causing major financial setbacks and study delays. This susceptibility compels companies to incur high expenses for specialized packaging and monitoring, straining budgets and limiting efficient market scalability in regions with developing infrastructure.

This logistical pressure is further amplified by the sheer volume of sensitive therapies currently in the pipeline. According to the 'Pharmaceutical Research and Manufacturers of America', in '2024', 'there were more than 8,000 medicines in clinical development' worldwide, a large portion of which are biologics requiring strict temperature maintenance. Managing the shipment of such a vast quantity of sensitive products heightens the risk of waste. Consequently, the elevated likelihood of supply chain failures in complex environments restricts the reach of clinical trials into new regions, thereby curbing the overall growth potential of the supplies market.

Market Trends

The move toward Decentralized Clinical Trial (DCT) supply logistics is reshaping the market by shifting care from standard investigator sites to patients' homes. This approach requires flexible supply chains that can handle direct-to-patient deliveries while strictly upholding temperature controls and chain of custody. To support this dispersed model, logistics providers are creating hyper-local distribution centers that ensure protocol compliance outside of traditional clinical environments. Confirming this shift, according to DHL Group, April 2025, in the 'DHL Group to Invest EUR 2 Billion by 2030 in DHL Health Logistics' press release, the firm has pledged '€2 billion' to bolster its life sciences logistics, specifically aiming to meet demand for specialized services in complex trial designs.

At the same time, the integration of Artificial Intelligence for Demand Forecasting is refining inventory management via predictive analytics. By analyzing data such as enrollment speeds and usage patterns, AI algorithms can accurately anticipate supply requirements, thereby minimizing drug waste and preventing shortages. This capability enables sponsors to adapt distribution strategies in real-time, ensuring materials are on hand exactly when required. Illustrating this development, according to Thermo Fisher Scientific, October 2025, in the 'Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI' press release, the company has incorporated artificial intelligence throughout its PPD clinical research division to 'improve the cycle time' of trials and speed up drug development.

Key Market Players

  • Thermo Fisher Scientific Inc.
  • Almac Group
  • Novo Holdings A/S
  • Marken LLP
  • PCI Pharma Services
  • Sharp Services LLC
  • Cencora, Inc.
  • Myonex LLC
  • Parexel International Corporation
  • ICON Plc

Report Scope

In this report, the Global Clinical Trial Supplies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Trial Supplies Market, By Clinical Phase

  • Phase I
  • Phase II
  • Phase III
  • Others

Clinical Trial Supplies Market, By Product & Services

  • Manufacturing
  • Storage & Distribution
  • Supply Chain Management

Clinical Trial Supplies Market, By Therapeutic Use

  • Oncology
  • CNS Diseases
  • Cardiovascular Diseases
  • Infectious Disease
  • Metabolic Disorders
  • Others

Clinical Trial Supplies Market, By End User

  • Pharmaceutical
  • Biologics
  • Medical device
  • Others

Clinical Trial Supplies Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Trial Supplies Market.

Available Customizations:

Global Clinical Trial Supplies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clinical Trial Supplies Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Clinical Phase (Phase I, Phase II, Phase III, Others)
    • 5.2.2. By Product & Services (Manufacturing, Storage & Distribution, Supply Chain Management)
    • 5.2.3. By Therapeutic Use (Oncology, CNS Diseases, Cardiovascular Diseases, Infectious Disease, Metabolic Disorders, Others)
    • 5.2.4. By End User (Pharmaceutical, Biologics, Medical device, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Clinical Trial Supplies Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Clinical Phase
    • 6.2.2. By Product & Services
    • 6.2.3. By Therapeutic Use
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Clinical Trial Supplies Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Clinical Phase
        • 6.3.1.2.2. By Product & Services
        • 6.3.1.2.3. By Therapeutic Use
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Clinical Trial Supplies Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Clinical Phase
        • 6.3.2.2.2. By Product & Services
        • 6.3.2.2.3. By Therapeutic Use
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Clinical Trial Supplies Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Clinical Phase
        • 6.3.3.2.2. By Product & Services
        • 6.3.3.2.3. By Therapeutic Use
        • 6.3.3.2.4. By End User

7. Europe Clinical Trial Supplies Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Clinical Phase
    • 7.2.2. By Product & Services
    • 7.2.3. By Therapeutic Use
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Clinical Trial Supplies Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Clinical Phase
        • 7.3.1.2.2. By Product & Services
        • 7.3.1.2.3. By Therapeutic Use
        • 7.3.1.2.4. By End User
    • 7.3.2. France Clinical Trial Supplies Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Clinical Phase
        • 7.3.2.2.2. By Product & Services
        • 7.3.2.2.3. By Therapeutic Use
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Clinical Trial Supplies Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Clinical Phase
        • 7.3.3.2.2. By Product & Services
        • 7.3.3.2.3. By Therapeutic Use
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Clinical Trial Supplies Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Clinical Phase
        • 7.3.4.2.2. By Product & Services
        • 7.3.4.2.3. By Therapeutic Use
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Clinical Trial Supplies Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Clinical Phase
        • 7.3.5.2.2. By Product & Services
        • 7.3.5.2.3. By Therapeutic Use
        • 7.3.5.2.4. By End User

8. Asia Pacific Clinical Trial Supplies Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Clinical Phase
    • 8.2.2. By Product & Services
    • 8.2.3. By Therapeutic Use
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Clinical Trial Supplies Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Clinical Phase
        • 8.3.1.2.2. By Product & Services
        • 8.3.1.2.3. By Therapeutic Use
        • 8.3.1.2.4. By End User
    • 8.3.2. India Clinical Trial Supplies Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Clinical Phase
        • 8.3.2.2.2. By Product & Services
        • 8.3.2.2.3. By Therapeutic Use
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Clinical Trial Supplies Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Clinical Phase
        • 8.3.3.2.2. By Product & Services
        • 8.3.3.2.3. By Therapeutic Use
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Clinical Trial Supplies Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Clinical Phase
        • 8.3.4.2.2. By Product & Services
        • 8.3.4.2.3. By Therapeutic Use
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Clinical Trial Supplies Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Clinical Phase
        • 8.3.5.2.2. By Product & Services
        • 8.3.5.2.3. By Therapeutic Use
        • 8.3.5.2.4. By End User

9. Middle East & Africa Clinical Trial Supplies Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Clinical Phase
    • 9.2.2. By Product & Services
    • 9.2.3. By Therapeutic Use
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Clinical Trial Supplies Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Clinical Phase
        • 9.3.1.2.2. By Product & Services
        • 9.3.1.2.3. By Therapeutic Use
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Clinical Trial Supplies Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Clinical Phase
        • 9.3.2.2.2. By Product & Services
        • 9.3.2.2.3. By Therapeutic Use
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Clinical Trial Supplies Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Clinical Phase
        • 9.3.3.2.2. By Product & Services
        • 9.3.3.2.3. By Therapeutic Use
        • 9.3.3.2.4. By End User

10. South America Clinical Trial Supplies Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Clinical Phase
    • 10.2.2. By Product & Services
    • 10.2.3. By Therapeutic Use
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Clinical Trial Supplies Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Clinical Phase
        • 10.3.1.2.2. By Product & Services
        • 10.3.1.2.3. By Therapeutic Use
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Clinical Trial Supplies Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Clinical Phase
        • 10.3.2.2.2. By Product & Services
        • 10.3.2.2.3. By Therapeutic Use
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Clinical Trial Supplies Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Clinical Phase
        • 10.3.3.2.2. By Product & Services
        • 10.3.3.2.3. By Therapeutic Use
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Clinical Trial Supplies Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Almac Group
  • 15.3. Novo Holdings A/S
  • 15.4. Marken LLP
  • 15.5. PCI Pharma Services
  • 15.6. Sharp Services LLC
  • 15.7. Cencora, Inc.
  • 15.8. Myonex LLC
  • 15.9. Parexel International Corporation
  • 15.10. ICON Plc

16. Strategic Recommendations

17. About Us & Disclaimer